disability

#ACTRIMS2021 – Benign Versus Aggressive MS ā€“ the Hunt for Clues

Editorā€™s note: TheĀ Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25ā€“27. GoĀ hereĀ to see the latest stories from the conference. While researchers make progress in pinpointing markers of disease progression in multiple sclerosis (MS), identifying those that signal…

Enrollment Complete in Phase 2 Trial Testing Temelimab

GeNeuroĀ has completed patient enrollment in its ProTEct-MS Phase 2 clinical trial evaluating temelimab as a treatment for multiple sclerosis (MS), the company announced. The study (NCT04480307), taking place at the Karolinska Institutetā€™s Academic Specialist Center (ASC) in Stockholm, Sweden, has enrolled 42 people with relapsing MS whose…

New Zealand Expands Patient Access to Funded MS Treatments

New Zealand will expand patient access to a list of funded treatments for multiple sclerosis (MS), starting on March 1. The government health agency, PHARMAC, will extend eligibility criteria to include MS patients with expanded disability status scale (EDSS) scores ranging from zero to six. EDSS is a validated…

New Spinal Cord Lesions Can Be Evident in Stable MS Patients

Asymptomatic damage to spinal nerves occurs even in clinically stable cases of multiple sclerosis (MS) and carries an increased risk for further lesions, a recent study suggests. Although a firm link between the asymptomatic loss of myelin in the spine and worsening disability remains to be found, this work…

Brain Changes in Relapsing MS Found to Follow Pattern

Changes in the amount of grey matter in specific regions of the brain appear to occur early in relapsing multiple sclerosis (MS), while structural changes in white matter happen late in disease progression. These were among the findings of a recent study that tracked the sequence of events in…

Myelin Ceramides Altered in MS, Study Finds

Levels of myelin sheath components called ceramides are altered in the blood of people with multiple sclerosis (MS) and may be linked with retinal degeneration and physical disability, a study has found.Ā  Specific ceramides were altered only in those with progressive…

Biogen Discontinues Development of Opicinumab for MS

BiogenĀ is discontinuing the clinical development of opicinumab,Ā its experimental treatment candidate forĀ multiple sclerosisĀ (MS), based on data from the Phase 2 AFFINITY clinical trial. The announcement, amid a third-quarter report, indicated that the study failed to meet both its main and secondary goals, without further details. The trial,…

#MSVirtual2020 – Ponesimod Superior to Aubagio in Delaying Disability Progression in Relapsing MS, Trial Data Show

Janssen Pharmaceuticalsā€™ investigational oral therapy ponesimod is superior to Sanofiā€™s Aubagio (teriflunomide) in delaying disability progression in adults with relapsing multiple sclerosis (MS), according to exploratory analyses of OPTIMUM clinical trial data. These and other findings from Janssenā€™s MS research program, including on the health…

#MSVirtual2020 ā€“ Zeposia Still Prevents Relapses in Relapsing MS Patients After 3 Years, Trial Data Show

Zeposia (ozanimod) oral capsules continue to safely and effectively prevent relapses and disability progression in people with relapsing forms of multiple sclerosis (MS), according to three-year data from a Phase 3 extension clinical trial. ā€œGaining insight into long-term therapeutic outcomes can enable clinicians to identify the most appropriate…